Screener
Acadia Pharmaceuticals ACAD Cash & Equivalents
Cash & Equivalents at other companies
Other financials
Where this comes from
Reported directly by Acadia Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue.
The source filing: Acadia Pharmaceuticals’s 10-Q, filed August 5, 2026. Open the filing →
- Filed
- Aug 4, 2026, 8:00 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-333243
FAQ
- What is Acadia Pharmaceuticals's cash & equivalents?
- Acadia Pharmaceuticals (ACAD) reported cash & equivalents of $384.99M in Q2 2026.
- How has Acadia Pharmaceuticals's cash & equivalents changed year-over-year?
- Acadia Pharmaceuticals's cash & equivalents increased by 51.8% year-over-year, from $253.64M to $384.99M.
- What is the long-term trend for Acadia Pharmaceuticals's cash & equivalents?
- Over 5 years (2020 to 2025), Acadia Pharmaceuticals's cash & equivalents has grown at a -11.4% compound annual growth rate (CAGR), from $326.03M to $177.7M.
- What does cash & equivalents mean?
- Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.
Ask your AI about Acadia Pharmaceuticals's cash & equivalents.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude